This Month in Psychopharmacology

Ketogenic Diet Shows Modest Short-Term Benefit in Treatment-Resistant Depression

Studies have suggested that a ketogenic diet –a high-fat, low-carbo...

Read More

Long-Term Impact of Cognitive Training on Dementia Risk: 20-Year Outcomes From a Randomized Trial

In older adults, cognitive training can facilitate long-term improv...

Read More

Preinjury Antidepressant Use Does Not Appear to Worsen Clinical Outcomes after TBI

Concerns have long circulated that serotonergic antidepressants may...

Read More

FDA Approves Milsaperidone for Schizophrenia and Acute Bipolar I Disorder

The FDA has approved milsaperidone for the treatment of schizophren...

Read More

Metformin Modestly Reduces BMI in Overweight Youth With Bipolar Disorders

Second-generation antipsychotics (SGAs) are first-line pharmacologi...

Read More

Serial Intravenous Ketamine Infusions Not Superior to Usual Inpatient Care for Depression

Serial IV ketamine infusions are increasingly used off-label for tr...

Read More

Efficacy and Tolerability of Antipsychotics for Acute Schizophrenia

Antipsychotic selection in schizophrenia remains an important, high...

Read More

FDA Grants Priority Review to Centanafadine for ADHD

While there are many stimulant and non-stimulant options targeting ...

Read More

FDA Removes Suicidal Ideation Warning From GLP-1 Drugs

The FDA has announced a significant update affecting several widely...

Read More

Synthetic THC Shows Promise for Agitation Management in Alzheimer’s Patients

A new randomized controlled trial by Rosenberg and colleagues offer...

Read More

NRX-101 Development Expanded to Include TMS for Depression

Treatment resistance is common in major depressive disorder, and tr...

Read More

FDA Approves Cariprazine for Pediatric Schizophrenia and Bipolar I Disorder

The FDA has expanded the indication for cariprazine to include pedi...

Read More